Our study of the effects of NAM were examined in vitro and in an animal model, not clinically, so further clinical investigations of the therapeutic potential of NAD+/SIRT3 on cognitive impairment associated with schizophrenia are now required. This evidence concerns the gene SIRT3 and schizophrenia.